Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

Basit Öğe Kaydı
dc.contributor.authorPowles, Thomas
dc.contributor.authorAlbiges, Laurence
dc.contributor.authorJalkanen, Katriina Johanna
dc.contributor.authorDe Velasco, Guillermo
dc.contributor.authorBurotto, Mauricio
dc.contributor.authorGhatalia, Pooja
dc.contributor.authorSuarez, Cristina
dc.date.accessioned2025-05-10T19:34:30Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAmerican-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU) -- JAN 25-27, 2024 -- San Francisco, CA
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipMerck Sharp Dohme LLC
dc.description.sponsorshipMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ,USA.
dc.identifier.doi10.1200/JCO.2024.42.4_suppl.361
dc.identifier.endpage361
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue4_SUPPL
dc.identifier.scopusqualityQ1
dc.identifier.startpage361
dc.identifier.urihttps://doi.org/10.1200/JCO.2024.42.4_suppl.361
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8549
dc.identifier.volume42
dc.identifier.wosWOS:001266676900083
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleBelzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu